2,812 results match your criteria Antiphospholipid Antibody Syndrome and Pregnancy


Characteristics of midluteal phase uterine artery hemodynamics in patients with recurrent pregnancy loss.

J Obstet Gynaecol Res 2019 Apr 11. Epub 2019 Apr 11.

Department of Reproductive Medical Center, The First People's Hospital of Yunnan Province, Kunming, China.

Aim: To study the association in resistance to uterine artery blood flow and recurrent pregnancy loss (RPL) and find its potential influencing factors.

Methods: A retrospective study was conducted in 870 RPL and 237 non-RPL patients visiting to the Clinic from January 2014 to February 2018. All participants underwent comprehensive examinations and were scanned by transvaginal Doppler ultrasonography during the midluteal phase to measure the pulsatility index (PI), resistance index (RI) and systolic/diastolic ratio (S/D) values of the left and right main uterine arteries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jog.13944DOI Listing
April 2019
1 Read

Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia.

Lupus 2019 Apr 10:961203319843343. Epub 2019 Apr 10.

1 Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Background: Hydroxychloroquine (HCQ) is regarded as a mainstay in the treatment of systemic lupus erythematosus (SLE) because of its efficacy in preventing flares, achieving remission, and reducing overall mortality. However, the impact of HCQ on pregnancy outcomes remains controversial.

Objective: We aimed to investigate the effect of HCQ on pregnancy outcomes in patients with SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319843343DOI Listing
April 2019
4 Reads

Systemic Lupus Erythematosus and Pregnancy: A Brief Review.

J Obstet Gynaecol India 2019 Apr 12;69(2):104-109. Epub 2019 Mar 12.

The Department of Obstetrics and Gynecology, Nowrosjee Wadia Maternity Hospital, Mumbai, India.

Systemic lupus erythematosus is a chronic multisystemic autoimmune disease that predominantly affects young women of childbearing age group. There is a complex immunologic interplay during pregnancy in patients with systemic lupus erythematosus. The pregnancy has direct impact on the disease where an increased rate of flares is noted, and lupus leads to increased risk of hypertensive diseases of pregnancy, preterm birth as well as miscarriages, particularly those with antiphospholipid antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13224-019-01212-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430271PMC
April 2019
2 Reads

Role of TLR‑4 in anti‑β2‑glycoprotein I‑induced activation of peritoneal macrophages and vascular endothelial cells in mice.

Mol Med Rep 2019 May 26;19(5):4353-4363. Epub 2019 Mar 26.

Department of Internal Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China.

Anti‑phospholipid syndrome (APS) is a systematic autoimmune disease that is associated with presence of antiphospholipid antibodies (aPL), recurrent thrombosis, and fetal morbidity in pregnancy. Toll‑like receptor‑4 (TLR‑4), a member of TLR family, is known to have a fundamental role in pathogen recognition and activation of innate immunity. The β2‑glycoprotein I (β2GPI), a protein circulating in the blood at a high concentration, is able of scavenging lipopolysaccharide (LPS) and clear unwanted anionic cellular remnants, such as microparticles, from the circulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mmr.2019.10084DOI Listing
May 2019
3 Reads

Antiphospholipid Antibodies Overlapping in Isolated Neurological Syndrome and Multiple Sclerosis: Neurobiological Insights and Diagnostic Challenges.

Front Cell Neurosci 2019 19;13:107. Epub 2019 Mar 19.

Department of Clinical Immunology and IdISSC, Hospital Clínico San Carlos, Madrid, Spain.

Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis, pregnancy morbidity and fetal loss caused by pathogenic autoantibodies directed against phospholipids (PL) and PL-cofactors. Isolated neurological APS may represent a significant diagnostic challenge, as epidemiological, clinical and neuroimaging features may overlap with those of multiple sclerosis (MS). In an open view, MS could be considered as an organ-specific anti-lipid (phospholipid and glycosphingolipid associated proteins) disease, in which autoreactive B cells and CD8+ T cells play a dominant role in its pathophysiology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fncel.2019.00107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433987PMC
March 2019
3 Reads

Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome.

Mod Rheumatol 2019 Mar 29:1-13. Epub 2019 Mar 29.

a Department of Obstetrics and Gynecology , Nagoya City University, Graduate School of Medical Sciences , Nagoya , Aichi , Japan.

Objective: The objective is to evaluate whether danaparoid is effective in improving the live birth rate in patients with obstetric antiphospholipid syndrome (oAPS).

Methods: This prospective study included 91 pregnancies of 60 patients with oAPS diagnosed according to criteria of the International Congress on APS. Live birth rates, adverse pregnancies and perinatal outcomes were compared among patients treated with danaparoid and low dose aspirin (danaparoid group, LDA), unfractionated heparin (UFH) and LDA (UFH group) and LDA and/or prednisolone (LDA group). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14397595.2019.1602241DOI Listing
March 2019
3 Reads

Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome.

Front Immunol 2019 14;10:460. Epub 2019 Mar 14.

Dipartimento di Medicina Sperimentale, Sapienza Università di Roma, Rome, Italy.

Antiphospholipid antibody syndrome (APS) is a systemic autoimmune disease characterized by arterial and/or venous thrombosis, pregnancy morbidity in the presence of circulating "anti-phospholipid antibodies" (aPL). One of the main target antigens of aPL is β-glycoprotein I (β-GPI). APS may occur as a primary syndrome or associated with Systemic Lupus Erythematosus (SLE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00460DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426766PMC
March 2019
1 Read

Complement in the Pathophysiology of the Antiphospholipid Syndrome.

Front Immunol 2019 14;10:449. Epub 2019 Mar 14.

Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland, OH, United States.

The antiphospholipid syndrome (APS) is characterized by thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). Complement is a system of enzymes and regulatory proteins of the innate immune system that plays a key role in the inflammatory response to pathogenic stimuli. The complement and coagulation pathways are closely linked, and expanding data indicate that complement may be activated in patients with aPL and function as a cofactor in the pathogenesis of aPL-associated clinical events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00449DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426753PMC
March 2019
1 Read

Absence of Distinct Immunohistochemical Distribution of Annexin A5, C3b, C4d, and C5b-9 in Placentas From Patients With Antiphospholipid Antibodies, Preeclampsia, and Systemic Lupus Erythematosus.

Pediatr Dev Pathol 2019 Mar 28:1093526619836025. Epub 2019 Mar 28.

1 Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital-Weill Cornell Medical College, New York, New York.

Introduction: In pregnancy, the presence of preeclampsia (PEC), systemic lupus erythematosus (SLE), and/or antiphospholipid antibody syndrome (APLS) is characterized by poor obstetric outcomes, with potential adverse effects for both mother and fetus. Although the histopathologic changes observed in these entities have been well established, the pathogenic mediators associated with tissue injury are poorly understood.

Methods: Forty placentas were evaluated, including 10 patients with preeclampsia, 9 with SLE, 11 with APLS, and 10 disease-free controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1093526619836025DOI Listing

The Extended Use of Eculizumab in Pregnancy and Complement Activation⁻Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys-The Future Is Now?

J Clin Med 2019 Mar 24;8(3). Epub 2019 Mar 24.

Department of Obstetrics and Gynecology, Helsinki University and Helsinki University Hospital, Haartmaninkatu 2, 00290 Helsinki, Finland.

Excessive complement activation is involved in the pathogenesis of many diseases and the kidney is an organ with particular susceptibility to complement-mediated injury. Apart from paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), there are several other diseases with clear evidence of complement activation affecting both maternal and fetal kidneys during pregnancy and causing long-term adverse outcomes. Several novel drugs have been recently developed for blocking the complement cascade, including purified plasma proteins, new monoclonal antibodies, recombinant proteins, small molecules, and small interfering RNA agents. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/2077-0383/8/3/407
Publisher Site
http://dx.doi.org/10.3390/jcm8030407DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463259PMC
March 2019
7 Reads

Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study.

BMJ Open 2019 Mar 20;9(3):e025649. Epub 2019 Mar 20.

Brest University Hospital, Brest, France.

Introduction: Recurrent miscarriage (RM), defined by three or more consecutive losses during the first trimester of pregnancy, affects 1%-2% of fertile couples. Standard investigations fail to reveal any apparent cause in ~50% of couples. However, on the basis of animal models and clinical studies, several hypotheses have been put forward concerning underlying mechanisms of RM: altered ovarian reserve, progesterone defect, thrombotic and/or endothelial dysfunction and immunological disturbances. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2018-025649DOI Listing
March 2019
1 Read

Impact of extractable nuclear antigen, anti-double stranded DNA, antiphospholipid antibody, and anticardiolipin antibody positivity on obstetrical complications and pregnancy outcomes.

Hum Antibodies 2019 ;27(2):135-141

Department of Biostatistics, Hacettepe University, Ankara, Turkey.

Background: Extractable nuclear antigen (ENA) and anti-double stranded DNA (anti-dsDNA) positivity and related diseases like systemic lupus erythematosus, Sjögren syndrome, and other autoimmune diseases are known to be associated with obstetrical complications and poor perinatal outcomes.

Objective: To demonstrate the importance of ENA, anti-dsDNA, antiphospholipid (APL), and anticardiolipin (ACL) antibody positivity on pregnancy outcomes.

Methods: Ninety one pregnant women with known ENA, anti-dsDNA, APL IgG and IgM, and ACL IgG and IgM antibody positivity were retrospectively compared with 91 randomly selected pregnant woman in terms of obstetrical complications and pregnancy outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/HAB-180359DOI Listing
January 2019
2 Reads

High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant.

Blood Adv 2019 Mar;3(5):769-776

Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Lupus anticoagulant (LA) has been associated with pregnancy complications and pregnancy loss. Identification of predictive factors could aid in deciding on therapeutic management. To identify risk factors for adverse pregnancy outcomes in high-risk women with persistently positive LA, we prospectively followed 82 women of childbearing age, of whom 23 had 40 pregnancies within the Vienna Lupus Anticoagulant and Thrombosis Study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018026948DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418496PMC
March 2019
4 Reads

Thrombotic risk factors in patients with antiphospholipid syndrome: a single center experience.

J Thromb Thrombolysis 2019 Mar 5. Epub 2019 Mar 5.

Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, 1305 York Avenue 7th Floor, New York, NY, 10021, USA.

Patients with primary or secondary antiphospholipid syndrome (APS) have an increased risk of recurrent venous, arterial thrombosis and pregnancy complications. Therefore, determining thrombotic risk is important when individualizing antithrombotic therapy in patients with APS. To identify thrombotic risk factors in a cohort of APS patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01836-7DOI Listing
March 2019
4 Reads

Low molecular weight heparin monotherapy for recurrent abortion with antiphospholipid system: A protocol of a systematic review.

Medicine (Baltimore) 2019 Feb;98(8):e14619

Department of Gynecology, First Affiliated Hospital of Jiamusi University, Jiamusi, China.

Background: Previous clinical studies reported low molecular weight heparin (LMWH) monotherpay has been utilized for the treatment of recurrent abortion (RCA) with antiphospholipid system (APS). However, its efficacy is still inconclusive. This systematic review aims to assess its efficacy and safety for patients with RCA and APS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014619DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408107PMC
February 2019
2 Reads

High detection rates of antithrombin deficiency and antiphospholipid syndrome in outpatients aged over 50 years using the standardized protocol for thrombophilia screening.

Thromb Res 2019 Apr 11;176:67-73. Epub 2019 Feb 11.

Krakow Center for Medical Research and Technology, John Paul II Hospital, Krakow, Poland; Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. Electronic address:

Introduction: Thrombophilia screening has limited detection efficiency. We assessed the detection rate when a standardized approach to thrombophilia-screened outpatients was used.

Methods: We analyzed 1185 patients (36. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2019.02.008DOI Listing
April 2019
2 Reads

Thrombophilia, risk factors and prevention.

Expert Rev Hematol 2019 Mar 26;12(3):147-158. Epub 2019 Feb 26.

a Haemorrhagic and Thrombotic Diseases Unit, Department of Medicine (DIMED) , Padova University Hospital , Padova , Italy.

Introduction: Fifty-three years after the first description of an inherited prothrombotic condition (antithrombin deficiency), our knowledge on hereditary and acquired causes of hypercoagulability that can predispose carriers to venous thromboembolism (VTE) has greatly improved. Areas covered: Main causes of hereditary thrombophilia are summarized alongside new prothrombotic mutations recently discovered. The main causes of acquired thrombophilia, and namely, antiphospholipid antibody syndrome and hyperhomocysteinemia, are also discussed together with other common acquired prothrombotic states characterized by an increase of procoagulant factors and/or a decrease of natural anticoagulants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583555DOI Listing
March 2019
1 Read

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases.

Autoimmun Rev 2019 Apr 15;18(4):406-414. Epub 2019 Feb 15.

Obstetrics and Gynaecology Department, High Risk Unit, Vall d'Hebron University Hospital, Universitat Autonoma, Barcelona, Spain.

Aim: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them up on a cohort of 1000 women with obstetric antiphospholipid syndrome (OAPS).

Methods: The European Registry of OAPS became a registry within the framework of the European Forum on Antiphospholipid Antibody projects and was placed on a website in June 2010. Thirty hospitals throughout Europe have collaborated to carry out this registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.12.006DOI Listing
April 2019
1 Read

Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.

Curr Opin Rheumatol 2019 May;31(3):231-240

Division of Rheumatology, Department of Internal Medicine, University of Michigan.

Purpose Of Review: Although antiphospholipid syndrome (APS) is best known for conveying increased risk of thrombotic events and pregnancy morbidity, thrombocytopenia is also recognized as a common association. In this review, we will explore the relationship between thrombocytopenia and APS, highlighting our evolving understanding - and persistent knowledge gaps - through clinically oriented questions and answers.

Recent Findings: A history of thrombocytopenia likely portends a more severe APS phenotype (including increased risk of thrombosis). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000595DOI Listing
May 2019
2 Reads

Outcomes of Pregnancy in Women With Inflammatory Myositis: A Retrospective Cohort From India.

J Clin Rheumatol 2019 Feb 1. Epub 2019 Feb 1.

From the Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.

Objectives: Idiopathic inflammatory myositis (IIM) commonly affects women in the childbearing age group. Both disease activity and immunosuppressants used may have adverse effects on fertility and outcomes of pregnancy. We explored these outcomes in a retrospective cohort of women with IIM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000996DOI Listing
February 2019
12 Reads

Laboratory Diagnostics in Thrombophilia.

Hamostaseologie 2019 Feb 31;39(1):49-61. Epub 2019 Jan 31.

Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.

A thrombophilic disorder is a hereditary or acquired condition that increases the risk of thrombosis. The most common hereditary thrombophilias that predispose to venous thrombosis in the Caucasian population are the heterozygous forms of the factor V Leiden and prothrombin G20210A mutation that are generally detected by direct DNA genotyping. Immunologic antigen assays and chromogenic or clot-based activity assays are used to identify deficiencies in the natural coagulation inhibitors antithrombin, protein C and protein S. Read More

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0039-1677840
Publisher Site
http://dx.doi.org/10.1055/s-0039-1677840DOI Listing
February 2019
14 Reads

In vitro fertilization and autoimmunity: Evidence from an observational study.

Eur J Obstet Gynecol Reprod Biol 2019 Mar 14;234:137-142. Epub 2019 Jan 14.

"Sapienza", Università di Roma, Dipartimento di Medicina Clinica e Molecolare, Facoltà di Medicina e Psicologia, Ospedale Sant'Andrea, Via Grottarossa 1035-1039, 00189, Roma, Italy. Electronic address:

Introduction: The aim of this study was to evaluate the prevalence of antiphospholipid antibodies (aPLs) in infertile women undergoing in vitro fertilization (IVF).

Method Of Study: From January 2012 to December 2017, 520 consecutive clinical records of infertile women undergoing IVF were evaluated. Among them, 100 consecutive clinical records of patients with positive autoantibodies were selected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejogrb.2018.12.042DOI Listing

Timing of initiation of low-molecular-weight heparin administration in pregnant women with antiphospholipid syndrome: a randomized clinical trial of efficacy and safety.

Int J Womens Health 2019 14;11:41-47. Epub 2019 Jan 14.

Department of Obstetrics and Gynecology, Mansoura University, Mansoura, Egypt,

Objective: We aimed to evaluate the effect of different timing of initiation of low-molecular-weight heparin (LMWH) administration on the pregnancy outcomes in women with antiphospholipid syndrome (APS).

Materials And Methods: A randomized controlled study was conducted on women with obstetrical APS. All participants were randomly divided at documentation of positive pregnancy test into two groups; early initiation group in which LMWH therapy was started once positive pregnancy test was established (in the fifth week of gestation), and later initiation group in which LMWH therapy was started after sonographic confirmation of fetal cardiac pulsation (in the seventh week of gestation). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJWH.S193293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336021PMC
January 2019
4 Reads

Cerebral Venous Sinus Thrombosis in Systemic Lupus Erythematosus.

Acta Med Indones 2018 Oct;50(4):343-345

Department of Internal Medicine, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia.

A 38-year-old woman presented with general weakness and vaginal bleeding. One month prior, she had been diagnosed with Evans syndrome (haemolytic anemia with positive Coombs test and thrombocytopenia) and was given oral steroid as maintenance therapy. Her serology examination was negative for hepatitis B, hepatitis C, and human immunodeficiency virus (HIV). Read More

View Article

Download full-text PDF

Source
October 2018
13 Reads

Mechanisms of Endothelial Dysfunction in Antiphospholipid Syndrome: Association With Clinical Manifestations.

Front Physiol 2018 21;9:1840. Epub 2018 Dec 21.

Grupo Reproducción, Departamento de Microbiología y Parasitología, Escuela de Medicina, Universidad de Antioquia, Medellín, Colombia.

The endothelium is a monolayer of cells that covers the inner surface of blood vessels and its integrity is essential for the maintenance of vascular health. Endothelial dysfunction is a key pathological component of antiphospholipid syndrome (APS). Its systemic complications include thrombotic endocarditis, valvular dysfunction, cerebrovascular occlusions, proliferative nephritis, deep vein thrombosis, and pulmonary embolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphys.2018.01840DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309735PMC
December 2018
4 Reads

Management of pregnant women with antiphospholipid antibodies.

Expert Rev Clin Immunol 2019 Apr 11;15(4):347-358. Epub 2019 Jan 11.

a Rheumatology Unit, Department of Medicine , University Hospital of Padua , Padua , Italy.

Introduction: Important advancements in pregnancy outcome have been reported in women with antiphospholipid antibodies (aPL), despite the fact that the treatment of aPL related pregnancy morbidity is not guided by consistent findings from well-designed trials. Areas covered: The current study draws a picture of the studies in the literature by performing a Medline search of relevant English language articles and reports our experience in managing different subsets of obstetric antiphospholipid syndrome (APS), defined on the basis of their clinical and laboratory characteristics. The management of pregnant women with non-criteria APS manifestations and that of aPL carriers during their first pregnancy is also examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1565995DOI Listing
April 2019
3 Reads

Obstetric APS and thrombosis; modelling future risks.

BJOG 2019 04 6;126(5):662. Epub 2019 Feb 6.

Department of Obstetrics and Gynaecology, Maastricht University Medical Centre (MUMC), Maastricht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1471-0528.15595DOI Listing
April 2019
2 Reads

[Comparison of the etiological constitution of two and three or more recurrent miscarriage].

Zhonghua Fu Chan Ke Za Zhi 2018 Dec;53(12):855-859

Center for Reproductive Medicine, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.

To compare the etiological constitution of recurrent miscarriage (RM) between patients with consecutive two and three or more miscarriages through combining the routine examination results and embryonic karyotype. Patients with a history of two or more consecutive clinical miscarriages (≤12 weeks of gestation) consulting in the RM clinic of the First Affiliated Hospital of Sun Yat-sen University from March 2011 to January 2016 were collected. Six hundred and ninety-six with detailed history recorded, routine clinical examinations of RM and at least once embryonic karyotype were ultimately enrolled in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-567x.2018.12.010DOI Listing
December 2018
11 Reads

Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome.

Tuberc Respir Dis (Seoul) 2019 Jan;82(1):53-61

Department of Pulmonary and Critical Care Medicine, Center for Pulmonary Hypertension and Venous Thrombosis, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Background: Antiphospholipid antibody syndrome (APS), an important cause of acquired thrombophilia, is diagnosed when vascular thrombosis or pregnancy morbidity occurs with persistently positive antiphospholipid antibodies (aPL). APS is a risk factor for unprovoked recurrence of pulmonary embolism (PE). Performing laboratory testing for aPL after a first unprovoked acute PE is controversial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4046/trd.2018.0045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304333PMC
January 2019
6 Reads

[Increased serum soluble-endoglin level and its clinical significance in antiphospholipid syndrome].

Beijing Da Xue Xue Bao Yi Xue Ban 2018 Dec;50(6):1027-1032

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.

Objective: To detect the serum levels of soluble endothelial glycoprotein endoglin (s-Eng) in patients with antiphospholipid syndrome (APS) and to evaluate the correlation between s-Eng levels and clinical features and laboratory parameters.

Methods: The levels of serum s-Eng were measured by enzyme linked immunosorbent assay (ELISA) in 139 patients with APS, 44 patients with SLE but no APS, 37 patients with primary Sjögren's syndrome (pSS), 23 patients with Bechet's disease (BD), 22 patients with systemic sclerosis (SSc) and 22 persistent anticardiolipin antibody (aCL) positive individuals without SLE or APS (simply aCL positive group) and 87 health controls (HC) without any auto-immune diseases. These APS patients included 64 primary APS patients and 75 APS patients secondary to SLE. Read More

View Article

Download full-text PDF

Source
December 2018
2 Reads

[Diagnosis and treatment of antiphospholipid antibody-related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome].

Beijing Da Xue Xue Bao Yi Xue Ban 2018 Dec;50(6):956-961

Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China.

Recurrent spontaneous abortion is one of the common complications in women of childbearing age during pregnancy. The immune factor accounts for a large proportion of many causes. Antiphospholipid antibody syndrome is the most common type of acquired thrombophilia disease. Read More

View Article

Download full-text PDF

Source
December 2018
2 Reads

The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome.

Front Pediatr 2018 27;6:362. Epub 2018 Nov 27.

Department of Rheumatology, University College London, London, United Kingdom.

Antiphospholipid syndrome (APS) is a rare autoimmune disease of unknown etiology that represents a leading cause of acquired thromboembolism and recurrent miscarriage. It is characterized by the persistent elevated presence of pathogenic antiphospholipid auto-antibodies directed against cardiolipin, ß2-glycoprotein-I, and/or a positive lupus anticoagulant test. As with many autoimmune disorders, the pathogenesis of APS is believed to be the result of a complex interaction between environmental triggers and genetic predisposition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fped.2018.00362DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277799PMC
November 2018
5 Reads

Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome.

Front Immunol 2018 20;9:2644. Epub 2018 Nov 20.

Immunology Department, Hospital 12 de Octubre, Madrid, Spain.

Antiphospholipid syndrome (APS) is an acquired autoimmune disorder defined by the presence of both clinical (thromboembolic events or pregnancy morbidity) and laboratory (antiphospholipid antibodies, aPL) manifestations. Despite their importance, several clinical manifestations strongly associated with APS such as livedo reticularis (LR), thrombocytopenia, sicca-ophthalmic(sicca), heart, or neurological manifestations are not included in the APS clinical classification criteria. Circulating immune complexes (CIC) formed by Beta-2-glycoprotein I (B2GPI) and aPL (B2-CIC) have been described and their presence has been related with thrombotic events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.02644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256181PMC
November 2018
21 Reads

Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy.

Front Neurol 2018 26;9:1001. Epub 2018 Nov 26.

Section of Neurology, Department of Translational Medicine University of Eastern Piedmont, Novara, Italy.

Antiphospholipid syndrome (APS) is an autoimmune antibody-mediated condition characterized by thrombotic events and/or pregnancy morbidity in association with persistent positivity to antiphospholipid antibodies (aPL). The nervous system is frequently affected, as intracranial vessels are the most frequent site of arterial pathology. Over the course of years, many other neurological conditions not included in the diagnostic criteria, have been associated with APS. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fneur.2018.01001
Publisher Site
http://dx.doi.org/10.3389/fneur.2018.01001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275383PMC
November 2018
12 Reads

Post-partum catastrophic antiphospholipid syndrome presenting with shock and digital ischaemia - A diagnostic and management challenge.

J Intensive Care Soc 2018 Nov 19;19(4):357-364. Epub 2018 Mar 19.

Intensive Care Medicine, Nepean Hospital, Kingswood, NSW, Australia.

Catastrophic antiphospholipid syndrome is a rare multisystem autoimmune condition characterised by rapid development of widespread thrombotic disease and subsequent multi-organ failure. It is the most severe complication of antiphospholipid syndrome, carrying significant morbidity and mortality. We report a patient with post-partum catastrophic antiphospholipid syndrome with cardiac, hepatic, renal and cutaneous manifestations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1751143718762343DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259081PMC
November 2018
3 Reads

Anti-phospholipid Antibody Syndrome Presenting as Huge Ascites: A Case Report.

Mymensingh Med J 2018 Oct;27(4):883-887

Dr Abed Hussain Khan, Assistant Professor, Department of Internal Medicine, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.

Antiphospholipid Syndrome (APS) is characterized by arterial, venous or small vessel thromboses and/or pregnancy morbidity in the presence of persistently elevated titers of antiphospholipid antibodies. Since virtually any organ can be involved, the clinical presentation of APS is very varied. Abdominal manifestations are rare but may be life-threatening, and include Budd-Chiari Syndrome. Read More

View Article

Download full-text PDF

Source
October 2018
11 Reads

Genome-wide DNA methylation analysis in primary antiphospholipid syndrome neutrophils.

Clin Immunol 2018 Nov 22;196:110-116. Epub 2018 Nov 22.

Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA. Electronic address:

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thromboembolic events and pregnancy loss. We sought to characterize the DNA methylation profile of primary APS in comparison to healthy controls and individuals with SLE. In primary APS neutrophils compared to controls, 17 hypomethylated and 25 hypermethylated CpG sites were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clim.2018.11.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413498PMC
November 2018
14 Reads

Antiphospholipid syndrome in obstetrics.

Authors:
M Kemp W Thomas

Lupus 2018 Oct;27(1_suppl):28-31

2 Department of Haematology, Haemophilia & Thrombophilia Centre, Addenbrooke's Hospital, Cambridge, UK.

Antiphospholipid syndrome (APS) covers a spectrum of clinical manifestations ranging from recurrent pregnancy loss and obstetric complications from placental dysfunction through to thrombotic disease. This article will focus on the common manifestations of the pregnancy-related complications of APS. This includes clinical manifestations, diagnosis and management, as general practitioners will need to be able to recognize the disorder and will also have patients under their care receiving treatment for APS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203318801664DOI Listing
October 2018
4 Reads

Thrombotic antiphospholipid syndrome.

Authors:
S Sciascia M Radin

Lupus 2018 10;27(1_suppl):21-27

1 Center of Research of Immunopathology and Rare Diseases - Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203318801686DOI Listing
October 2018
7 Reads

New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats.

Haematologica 2019 Apr 15;104(4):819-826. Epub 2018 Nov 15.

Istituto Auxologico Italiano, IRCCS, Laboratory of Immuno-Rheumatology, Milan, Italy

Clinical studies have reported different diagnostic/predictive values of antibodies to domain 1 or 4/5 of βglycoproteinI in terms of risk of thrombosis and pregnancy complications in patients with antiphospholipid syndrome. To obtain direct evidence for the pathogenic role of anti-domain 1 or anti-domain 4/5 antibodies, we analyzed the pro-coagulant effect of two groups of 5 sera IgG each reacting selectively with domain 1 or domain 5 in lipopolysaccharide (LPS)-treated rats. Antibody-induced thrombus formation in mesenteric vessels was followed by intravital microscopy, and vascular deposition of βglycoproteinI, human IgG and C3 was analyzed by immunofluorescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.198119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442945PMC
April 2019
9 Reads

PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome.

Front Immunol 2018 22;9:2413. Epub 2018 Oct 22.

Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom.

APS is an autoimmune disease in which antiphospholipid antibodies (aPL) cause vascular thrombosis and pregnancy morbidity. In patients with APS, aPL exert pathogenic actions by binding serum beta-2-glycoprotein I (β2GPI) via its N-terminal domain I (DI). We previously showed that bacterially-expressed recombinant DI inhibits biological actions of IgG derived from serum of patients with APS (APS-IgG). Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.02413
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.02413DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204385PMC
October 2018
16 Reads

Zonal cortical scarring and tubular thyroidization in kidney biopsies of patients with SLE-histologic indicator for antiphospholipid antibodies.

Lupus 2018 Dec 7;27(14):2236-2244. Epub 2018 Nov 7.

2 Department of Pathology, Division of Renal and Transplant Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Antiphospholipid antibody syndrome (APS) is an acquired prothrombotic autoimmune disease caused by the presence of antibodies against anionic phospholipids or plasma proteins bound to phospholipids on cell membranes. It can be a primary disease or secondary to other autoimmune diseases, most commonly systemic lupus erythematosus (SLE). Laboratory testing for antiphospholipid antibodies (aPL) may be only transiently positive, so APS could be missed until a catastrophic thrombotic episode or pregnancy morbidity occurs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203318809177DOI Listing
December 2018
8 Reads

Antiphospholipid syndrome: state of the art on clinical practice guidelines.

RMD Open 2018 18;4(Suppl 1):e000785. Epub 2018 Oct 18.

Rheumatology and Clinical Immunology Unit, Civil Hospital, Brescia, Italy.

Antiphospholipid syndrome (APS) is a rare disease characterised by venous and/or arterial thrombosis, pregnancy complications and the presence of specific autoantibodies called antiphospholipid antibodies. This review aims to identify existing clinical practice guidelines (CPG) as part of the ERN ReCONNET project, aimed at evaluating existing CPGs or recommendations in rare and complex diseases. Seventeen papers providing important data were identified; however, the literature search highlighted the scarceness of reliable clinical data to develop CPGs. Read More

View Article

Download full-text PDF

Source
http://rmdopen.bmj.com/lookup/doi/10.1136/rmdopen-2018-00078
Publisher Site
http://dx.doi.org/10.1136/rmdopen-2018-000785DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203101PMC
October 2018
39 Reads

Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women.

Arthritis Res Ther 2018 Nov 6;20(1):249. Epub 2018 Nov 6.

AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, 27 Rue du Faubourg Saint Jacques, 75014, Paris, France.

Objective: Although one of the three obstetric manifestations of antiphospholipid syndrome (APS) is intrauterine fetal death (IUFD), little is known about it in this context. We report the first large series of patients with APS and IUFD.

Methods: We retrospectively analyzed the history and clinical data of women at four French hospitals. Read More

View Article

Download full-text PDF

Source
https://arthritis-research.biomedcentral.com/articles/10.118
Publisher Site
http://dx.doi.org/10.1186/s13075-018-1745-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235231PMC
November 2018
12 Reads

[Clinical study of maternal and infant outcomes in patients with lupus nephritis complicated with pregnancy].

Zhonghua Yi Xue Za Zhi 2018 Oct;98(37):2982-2986

Department of Rheumatology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.

To investigate the outcomes and associated factors for adverse pregnancy outcomes (APO) in pregnant patients with lupus nephritis (LN). The clinical data of 139 LN pregnant patients from from 2009 to 2017 in the First Affiliated Hospital of Sun Yat-sen University were analyzed retrospectively. Totally, 105 LN were diagnosed before pregnancy and 34 were newly diagnosed during pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0376-2491.2018.37.006DOI Listing
October 2018
2 Reads

Clinical profiles and risk assessment in patients with antiphospholipid antibodies.

Expert Rev Clin Immunol 2019 01 13;15(1):73-81. Epub 2018 Nov 13.

a Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine , Hokkaido University , Sapporo , Japan.

Introduction: Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia associated with the presence of persistent antiphospholipid antibodies (aPL). Owing to recent studies, not only APS patients but also incidentally-identified, asymptomatic aPL carriers are able to be stratified in terms of the risk of future thrombotic events, according to the variety and the titer of positive aPL tests and to the non-thrombotic, aPL-associated clinical manifestations. Areas covered: Here, we critically review (1) criteria manifestations of APS, (2) non-criteria manifestations of APS, (3) risk assessment in patients with APS and in aPL carriers, and (4) the potential role of primary thrombosis prophylaxis in aPL carriers. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1543025DOI Listing
January 2019
4 Reads

Antiphospholipid syndrome and pregnancy.

G Ital Dermatol Venereol 2019 Jun 29;154(3):277-285. Epub 2018 Oct 29.

Unit of Surgical, Microsurgical and Medical Sciences, Department of Dermatology, University of Sassari, Sassari, Italy.

Antiphospholipid syndrome (APS) is an autoimmune thrombophilic condition characterized by the onset of venous and/or arterial thrombosis, often multiple, and pregnancy morbidity in a background of antiphospholipid antibodies (aPL) positivity. Some patients can be carrier of aPL with no clinical symptoms, in other cases clinical manifestation can range from the classical presentation to an acute life-threatening condition named catastrophic APS. APS can be considered as primary or associated to other disease, however pregnancy acts as a triggering factor on a susceptible background that lead to the clinical manifestations through immunological and non-immunological mechanism. Read More

View Article

Download full-text PDF

Source
https://www.minervamedica.it/index2.php?show=R23Y9999N00A181
Publisher Site
http://dx.doi.org/10.23736/S0392-0488.18.06152-7DOI Listing
June 2019
17 Reads

Obstetric antiphospholipid syndrome.

Lupus Sci Med 2018 25;5(1):e000197. Epub 2018 Sep 25.

Unit of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

The present clinical and laboratory classification criteria for antiphospholipid syndrome (APS) were established in Sydney, Australia, in 2006. In this review, we focus on the obstetric subset of APS (OAPS), defined by persistent positivity for antiphospholipid antibodies together with either early recurrent pregnancy loss, early fetal death, stillbirth or premature birth <34 gestational weeks due to pre-eclampsia, eclampsia and placental insufficiency. It is important to diagnose these cases since most women suffering from OAPS can, when given appropriate treatment, have successful pregnancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/lupus-2016-000197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195166PMC
September 2018
26 Reads

Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I.

Front Immunol 2018 28;9:2244. Epub 2018 Sep 28.

Imperial College Vascular Sciences National Heart & Lung Institute, Imperial Centre for Translational and Experimental Medicine (ICTEM), London, United Kingdom.

Antiphospholipid antibodies (aPL), the serological hallmark of antiphospholipid syndrome (APS), are a heterogeneous group of autoantibodies raised against circulating blood proteins. Of these proteins, the phospholipid-binding b2-glycoprotein I (β2GPI) is considered to be the main autoantigen in APS. Indeed, IgG antibodies targeting b2GPI (ab2GPI) directly cause both thrombosis and pregnancy morbidity in several mouse models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.02244DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173128PMC
September 2018
5 Reads

Severe Preeclampsia, Antiphospholipid Syndrome, and Ulnar Artery Thrombosis in a Teenage Pregnancy: A Rare Association.

Case Rep Obstet Gynecol 2018 18;2018:1794723. Epub 2018 Sep 18.

University Unit of Obstetrics and Gynaecology, Teaching Hospital, Mahamodara, Galle, Sri Lanka.

Antiphospholipid syndrome (APS) is associated with vascular thrombosis and pregnancy complications. It causes recurrent miscarriage and it is associated with other adverse pregnancy outcomes such as preterm delivery, intrauterine growth restriction, preeclampsia, and HELLP syndrome. Obstetric morbidity is one of the major manifestations of APS with a wide variety of clinical manifestations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/1794723DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167596PMC
September 2018
1 Read